Theralase Technologies Inc. (TSXV:TLT)
Canada · Delayed Price · Currency is CAD 0.3050
-0.0150 (-4.69%)
May 1, 2026, 3:55 PM EST
Theralase Technologies Earnings Call Transcripts
Fiscal Year 2025
-
Enrollment in the pivotal bladder cancer study is nearing completion, with strong interim efficacy and safety data supporting a planned regulatory submission in late 2026. Financial discipline continues, with new capital raised and strategic initiatives underway to expand the pipeline and pursue a U.S. listing.
Fiscal Year 2024
-
Revenue declined 3% year-over-year, with net loss narrowing due to lower R&D spending. Strong clinical results in the Phase II bladder cancer study support ongoing regulatory and funding efforts, while the company pursues additional financing and strategic partnerships.